Geographic and Segment Information - Schedule of Segment Income of LivaNova’s Reportable Segments (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2025 |
Mar. 31, 2025 |
Sep. 30, 2024 |
Jun. 30, 2024 |
Mar. 31, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Sep. 30, 2024 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
Segment Reporting Information [Line Items] | ||||||||||
Net revenue | $ 352,524 | $ 318,575 | $ 669,379 | $ 613,487 | ||||||
Cost of sales | 113,536 | $ 100,601 | $ 97,091 | 103,697 | $ 91,704 | 214,137 | 195,401 | $ 292,492 | $ 399,953 | $ 397,725 |
Selling, general, and administrative | 137,780 | 129,146 | $ 127,426 | 125,131 | 125,681 | 266,926 | 250,812 | $ 378,238 | 508,876 | 502,699 |
Research and development | 47,185 | 44,737 | 85,064 | 90,401 | ||||||
Cardiopulmonary | ||||||||||
Segment Reporting Information [Line Items] | ||||||||||
Cost of sales | 84,920 | 76,279 | 334,326 | 306,359 | ||||||
Selling, general, and administrative | $ 53,959 | $ 46,563 | $ 199,747 | $ 191,571 | ||||||
Operating Segments | ||||||||||
Segment Reporting Information [Line Items] | ||||||||||
Total | 87,427 | 74,439 | 164,471 | 135,828 | ||||||
Operating Segments | Cardiopulmonary | ||||||||||
Segment Reporting Information [Line Items] | ||||||||||
Net revenue | 199,272 | 173,714 | 375,592 | 329,605 | ||||||
Cost of sales | 95,465 | 86,606 | 180,385 | 162,885 | ||||||
Selling, general, and administrative | 56,012 | 50,941 | 109,971 | 97,504 | ||||||
Research and development | 16,465 | 13,835 | 28,509 | 25,781 | ||||||
3T litigation provision | (77) | 2,705 | 629 | 9,097 | ||||||
Total | 31,407 | 19,627 | 56,098 | 34,338 | ||||||
Operating Segments | Neuromodulation | ||||||||||
Segment Reporting Information [Line Items] | ||||||||||
Net revenue | 151,670 | 142,876 | 290,563 | 276,748 | ||||||
Cost of sales | 14,769 | 12,203 | 28,155 | 22,531 | ||||||
Selling, general, and administrative | 51,097 | 46,099 | 98,667 | 91,793 | ||||||
Research and development | 29,784 | 29,762 | 55,368 | 60,934 | ||||||
3T litigation provision | 0 | 0 | 0 | 0 | ||||||
Total | $ 56,020 | $ 54,812 | $ 108,373 | $ 101,490 |